uBiome Appoints Dr. Jason Yamaki, PharmD, PhD, Assistant Professor of Pharmacy at Chapman University, to its Scientific Advisory Board
SAN FRANCISCO, Jan. 8, 2019
SAN FRANCISCO, Jan. 8, 2019 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announces the addition of Dr. Yamaki, PharmD, PhD, Assistant Professor in the School of Pharmacy at Chapman University, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Yamaki will bring to uBiome expertise in infectious disease, antibiotic resistance, and host-response. The appointment will help uBiome continue its advancement in human microbiome research.
"Dr. Yamaki's dedication to exploring patient outcomes and host response in various virulent and resistant infections is admirable and has produced exciting results," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "We look forward to utilizing his expertise with his addition to our board of scientific advisors."
Dr. Yamaki is an Assistant Professor in the School of Pharmacy at Chapman University. He completed his PharmD and PhD degrees at the University of Southern California School of Pharmacy, where he later was a Postdoctoral Research Associate and a lecturer in the Infectious Disease module. His current research interest is in infectious disease, particularly molecular and pharmacological approaches to addressing therapeutic challenges of treating multidrug-resistant and highly virulent bacteria. Dr. Yamaki is a member of several associations, including the American Society for Microbiology, the California Pharmacists Association, the American College of Clinical Pharmacy, the Society of Infectious Disease Pharmacists, and the American Association of Colleges of Pharmacy. He has been awarded the American Society for Microbiology Infectious Disease Fellow Travel Grant (2010), USC School of Pharmacy Best Research Assistant and Teaching Award (2012), and the USC Clinical and Translational Science Institute pilot study award as the Co-Investigator (2013).
About joining uBiome's Scientific Advisory Board, Dr. Yamaki said, "I am thrilled to be able to contribute to the uBiome board, particularly at this time where the microbiome is increasingly becoming recognized for affecting or being affected by various diseases, infectious and non-infectious. I believe uBiome has the potential to be a catalyst in providing individualized microbiome information to patients, providers, and researchers, to advance health and science."
In addition to Dr. Yamaki, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company's Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children's Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.